Silencing plasmacytoma variant translocation 1 promotes the anticancer activity of sorafenib in papillary thyroid carcinoma cells

Background: Sorafenib is an effective treatment for radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC), but adverse events limit its use. We investigated the synergistic anticancer effects of silencing lncRNA-PVT1 and sorafenib in papillary thyroid carcinoma (PTC) cell lines. Methods: : B-CPAP, TPC-1, IHH-4 and K1 papillary thyroid carcinoma cell lines were used. A small interfering RNA (siRNA)- PVT1 sequence was used to silence lncRNA-PVT1 expression. Cell proliferation, migration and invasion, apoptosis, and cell cycle assays were conducted following PVT1 silencing and/or sorafenib treatment. Results: : Sorafenib had inhibitory effects on PTC cell lines, and the cell survival rate decreased with increasing concentrations. LncRNA- PVT1 knockdown combined with 9 μM sorafenib in B-CPAP cells and 13 μM sorafenib in TPC-1 cells synergistically reduced the number of colonies formed, reduced invasion and migration, and promoted cell apoptosis. Conclusion: Sorafenib had inhibitory effects on TPC-1, B-CPAP, IHH4, and K1 cells, and lncRNA-PVT1 knockdown combined with sorafenib in B-CPAP and TPC-1 cells synergistically reduced the number of colonies formed, reduced invasion and migration, and promoted cell apoptosis.